Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Fremanezumab is a humanized monoclonal antibody directed against the human calcitonin gene-related peptide involved in the pathophysiology of migraine, which is used to prevent migraines. Subcutaneous administration monthly or every 3 months.
At the date of the last update we found no published data on its excretion in breast milk.
Its very high molecular weight makes it very difficult to pass into breast milk. (Stratigakis 2023)
Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed. (Anderson 2021)
Possible adverse reactions are very rare and not serious. (EMA 2023, Teva 2020)
See below the information of this related product: